<DOC>
	<DOCNO>NCT00165737</DOCNO>
	<brief_summary>Twenty-four week , prospective , randomize , double-blind , placebo-controlled , parallel-group study .</brief_summary>
	<brief_title>Donepezil Hydrochloride ( E2020 ) Dementia Associated With Cerebrovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Age range : Adult patient ( &gt; 40 year old ) 2 Possible Probable Dementia associate cerebrovascular disease define NINDSAIREN Criteria dementia great 3 month duration . 3 . Radiological evidence cerebrovascular disease . 4 . Sex distribution : Both men woman . Women childbearing potential ( &lt; 1 year post menopausal ) must willing practice effective contraception negative serum BHCG Screening . Pregnant and/or lactate female exclude . 5 . Race Health : Any generally healthy , ambulatory ambulatory aid ( i.e. , walker , cane wheelchair ) outpatient . Vision hearing ( glass , contact lens , hear aid permissible ) , speech , motor function comprehension must sufficient compliance test procedure . 6 . Patients risk factor hypertension cardiac disease may enrol study , provide hypertension medication control ( supine diastolic BP &lt; 95 mm Hg ) cardiac disease ( e.g . angina pectoris , congestive heart failure , right bundle branch block , arrhythmia ) stable appropriate medication 3 month prior Screening . Peripheral vascular disease must stable 3 month prior Screening . No elective surgical procedure plan course study ( e.g. , vascular bypass procedure coronary artery bypass surgery ) . 7 . Patients risk factor diabetes mellitus may enrol study , provide patient 's disease stable recent ( within 3 month ) admission diabetic ketoacidosis , hyperosmolar coma , hypoglycemia . Patients noninsulindependent diabetes may enroll study control diet oral medication . All diabetic patient must HbA1c concentration &lt; =10 % plasma glucose concentration &lt; = 250 mg/dL . 8 . Patients risk factor stroke may enrol study , provide disease process stable control medication great 3 month prior Screening . Patients receive anticoagulation warfarin eligible inclusion study International Normalized Ratio ( INR ) prothrombin time within therapeutic range prophylaxis ( 1.43.0 ) dose warfarin stable . Patients prosthetic heart valve , require full anticoagulation , stable ( &gt; = 3 month ) INR range 2.53.5 . 9 . Patients take previously approve cholinesterase inhibitor ( e.g. , Aricept. , Exelon. , Reminyl. , Cognex . ) memantine ( Ebixa , Akinatol ) allow provided medication discontinue least six ( 6 ) week prior Screening . 10 . Patients thyroid disease may include study , provide euthyroid treatment . 11 . Patient study partner willing participate provide write Informed Consent prior expose studyrelated procedure .</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Dementia cerebrovascular disease</keyword>
</DOC>